B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

known as B lymphocytes and T lymphocytes. People commonly refer to these as B cells and T cells. The job of T cells is to help the body kill cancer cells and control the immune response to foreign ...

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.